ArticleGynecologic oncology reports2026
Intracranial activity of mirvetuximab soravtansine in platinum-resistant high-grade serous ovarian cancer: Insights from a patient with central nervous system metastasis.
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ovarian cancer is the most lethal gynaecologic malignancy, often diagnosed at advanced stages due to nonspecific early symptoms. Although most patients initially respond to platinum-based chemotherapy, recurrence and resistance occur in the majority, leading to poor prognosis and limited treatment options. Recently, a novel antibody-drug conjugate has demonstrated significant clinical benefit in platinum-resistant high-grade serous ovarian cancer, offering a promising new therapeutic strategy in this historically challenging disease setting. Methods: We report a case of a 66-year-old woman with platinum-resistant high-grade serous ovarian cancer and a central nervous system metastasis who was started on fourth-line palliative treatment with mirvetuximab soravtansine, an antibody-drug conjugate targeting folate receptor-alpha. Following the second cycle, a significant reduction of the left parasagittal subcortical lesion was observed, from 19 × 15 mm to 11 × 6 mm, with complete resolution of vasogenic edema and mass effect, demonstrating intracranial activity of mirvetuximab soravtansine. Conclusion: To our knowledge, no published studies or case reports have yet documented central nervous system activity of mirvetuximab soravtansine in ovarian cancer. This case highlights a potential new therapeutic role for this agent in patients with ovarian cancer and central nervous system involvement and underscores the need for prospective clinical trials to rigorously assess its central nervous system penetration and efficacy in larger patient cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.